Synaffix, a biotechnology company focused on enabling antibody-drug conjugates (ADCs) with superior therapeutic index based on its proprietary ADC technology platform, announces that ADC Therapeutics SA has expanded its existing collaboration to explore additional applications, including DAR1, of Synaffix' site-specific conjugation technologies.
Under the expanded collaboration, ADC Therapeutics has been granted non-exclusive rights for two additional programs, which brings the total number of programmes using Synaffix' ADC technologies to five. ADC Therapeutics also gains access to the latest innovative extensions of Synaffix' proprietary GlycoConnect platform, including DAR1 technology that enables stable attachment of just a single drug per antibody.
Synaffix is eligible to receive upfront, milestone and royalty payments tied to each program. Further financial details are not disclosed.
Peter van de Sande, CEO of Synaffix said: "We are very pleased to see the rapid progression of ADC Therapeutics' programmes that have been developed using our GlycoConnect ADC technology platform, and the multiple collaboration expansions that have followed our original agreement."
"We look forward to continuing to work closely with the ADC Therapeutics team as they translate more product candidates using GlycoConnect into the clinic," van de Sande added.
Synaffix entered into the original commercial license agreement with ADC Therapeutics in October 2016. ADC Therapeutics is responsible for the research, development, manufacturing and commercialisation of any resulting ADC products, and Synaffix is responsible for the manufacturing of components specifically related to its proprietary ADC technologies.
